A clinical investigator is conducting a randomized, double-blind, placebo-controlled trial to evaluate the efficacy of a new monoclonal antibody targeting interleukin-5 (IL-5) for the prevention of severe exacerbations in patients with uncontrolled eosinophilic asthma. A total of 2,000 patients are enrolled and equally divided into two groups: one receiving the monoclonal antibody and the other receiving a placebo. All patients are followed for 1 year. During the follow-up period, 150 patients in the placebo group and 100 patients in the treatment group experience at least one severe asthma exacerbation. Which of the following is the number needed to treat to prevent one additional severe asthma exacerbation in this patient population over 1 year?
- A3
- B10
- 20Cevap
- D50
- E67